Noxopharm Investor Briefing – 8 July

Noxopharm (ASX: NXO) is an Australian-based, clinical stage drug development company which focuses on two areas of drug technology. The first is the potential benefit to cancer patients in being able to increase their responsiveness to standard of care chemotherapies and radiotherapies. Veyonda is the first pipeline drug candidate, with later generation drug candidates under investigation in an R&D program. The second area relates to the technology behind Veyonda and the opportunity it offers to exploit the broader therapeutic opportunities of isoflavonoid compounds.